Biosimilars

COVID-19

Cataract Surgery

Cataract

Cataract Therapeutics

Clinical Diagnosis

Cornea

Dry Eye Awareness

Dry Eye

Gene Therapy

Geographic Atrophy

IOL Advances

Imaging

Glaucoma Awareness

Glaucoma Insights

Therapeutic Glaucoma

Interventional Glaucoma

Ocular Allergy

Ocular Surface Disease

Optic Relief

Optometry

Pediatrics

Pharmacy

Indispensable

Practice Management

Presbyopia

Ptosis

Refractive Surgery

Refractive

Retina

Surgery

Technology

Therapeutics

Understanding Antibiotic Resistance

Workplace

News

All News

Contributors

Money Matters

Media

All Videos

Expert Interviews

Medical World News

Podcasts

Case Based Roundtable Series

Case of the Quarter

EyeView

Grand Rounds

Insights

Rapid Readout

Viewpoints

What’s Your WhEYE?

Conferences

Conference Coverage

Conference Listing

Events

Publications

Digital Edition

Europe Ophthalmology Times

Modern Retina

Supplements and Featured Publications

Partners

Subscribe

Resources

Job Board

Videos

At the Envision Summit 2025 in San Juan, Puerto Rico, Mike Farkas, MD, discussed gene therapy research for retinal degenerations that sidetracks the current "status quo" therapies of AAV-based replacement and CRISPR-Cas9 genome editing. 

Envision Summit 2025: Beyond the status quo in gene therapy

Articles

Risk factors vary in both short-term and long-term periods following Boston Type 1 keratoprosthesis surgery.

Retinal detachment risk after B1KPro

Children experienced sudden vision loss, visual field constriction, nyctalopia and dyschromatopsia following febrile illness.

Hyperacute outer retinal dysfunction may be an underrecognized pediatric disorder

Direct selective laser trabeculoplasty enhances the experience for both patients and physicians, he notes, while also mitigating issues related to poor adherence and ocular surface disease from topical therapy.

Thomas W. Samuelson, MD, shares clinical perspectives on DSLT, SLT, and glaucoma management

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic community.

About

Advertise

Privacy

Editorial Info

Editorial Board

Terms and Conditions

Contact Us

Do Not Sell My Personal Information

Ophthalmology Times - Ophthalmology news, articles, and events

Facebook

Instagram

LinkedIn

Spotlight

Clinical

Glaucoma

View

Visus Therapeutics CEO Ben Bergo shares an update on the status of its lead product candidate for presbyopia treatment as well as what's in the company's pipeline for 2021.

Visus CEO updates on lead product candidate, 2021 pipeline